Fidelity Investments’s Traws Pharma TRAW Stock Holding History

Fidelity Investments’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Sell	2 -21	-91%	-$29	﹤0.01%	5554
2026 Q1	$42	Buy	23 +21	+1,050%	+$39	﹤0.01%	5305
2025 Q4	$2	Hold	2	–	–	﹤0.01%	5404
2025 Q3	$4	Hold	2	–	–	﹤0.01%	5351
2025 Q2	$3	Hold	2	–	–	﹤0.01%	5305
2025 Q1	$5	Buy	+2	New	+$10	﹤0.01%	5261
2024 Q3	–	Hold	0	–	–	–	5765
2024 Q2	–	Sell	-40	Closed	-$645	–	5676
2024 Q1	$1.01K	Buy	+40	New	+$771	﹤0.01%	4780
2023 Q3	–	Hold	0	–	-$4	–	5556
2023 Q2	–	Hold	0	–	–	–	5324
2023 Q1	–	Hold	0	–	–	–	5243
2021 Q4	–	Sell	-16	Closed	-$2K	–	5015
2021 Q3	$2K	Buy	+16	New	+$2.06K	﹤0.01%	4061
2014 Q4	–	Sell	-3	Closed	-$615K	–	2851
2014 Q3	$615K	Sell	3 -1	-25%	-$285K	﹤0.01%	2601
2014 Q2	$1.2M	Sell	4 -9	-69%	-$2.66M	﹤0.01%	2482
2014 Q1	$4.79M	Sell	13 -4	-24%	-$2.41M	﹤0.01%	2219
2013 Q4	$10.7M	Buy	17 +11	+183%	+$10.4M	﹤0.01%	1947
2013 Q3	$8.56M	Buy	+6	New	+$8.58M	﹤0.01%	2001

Other funds holding TRAW

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Fidelity Investments's TRAW Position: Q2 2026 in Review

Fidelity Investments reduced its Traws Pharma (TRAW) stake by 91% in Q2 2026, selling an estimated $29 and leaving 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #5554.

Fidelity Investments first reported a position in TRAW in Q3 2013 and has held it in 13 quarters since. The position peaked at $10.7M in Q4 2013. 34 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

Fidelity Investments held 2 shares of Traws Pharma worth $2 as of Q2 2026.
Fidelity Investments sold 21 Traws Pharma shares in Q2 2026, an estimated $29.
Traws Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5554 holding.
Fidelity Investments first reported a position in Traws Pharma in Q3 2013 and has held it in 13 quarters since.
Fidelity Investments's Traws Pharma position peaked at $10.7M in Q4 2013.
34 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.